TL;DR
FDA vaccine advisory committee unanimously supported Moderna’s mRNA flu vaccine, mRNA-1010, after previous agency disputes. The FDA’s final decision is pending, with potential widespread impact on flu vaccination options.
FDA vaccine advisory committee members voted 9–0 to recommend approval of Moderna’s mRNA flu vaccine, mRNA-1010, marking a significant step forward after recent agency disputes over the review process.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed extensive data on Moderna’s mRNA-1010, including results from a Phase 3 trial involving over 40,000 adults aged 50 and older. The data showed the vaccine was approximately 27 percent more effective against seasonal flu than standard flu shots. Additionally, a smaller trial involving nearly 3,000 adults aged 65 and older indicated the vaccine produced stronger immune responses than high-dose flu vaccines, which are typically recommended for this age group.
The safety profile of the vaccine was generally favorable, with committee members praising the robustness of the data. An FDA scientist also supported the vaccine’s efficacy, with committee member Flor Munoz-Rivas highlighting the well-conducted studies and potential for the mRNA platform to improve flu prevention. The approval recommendation follows months of controversy, including a previous rejection by a Trump-era FDA official who refused to review Moderna’s application, claiming the trial data was not adequate.
Moderna expressed satisfaction with the committee’s support, with CEO Stéphane Bancel stating that the company looks forward to working with the FDA to finalize approval. The FDA has set a deadline of August 5 to decide whether to approve the vaccine, which Moderna intends to release later this year if approved.
Why the FDA Approval Vote Matters for Flu Prevention
The committee’s unanimous support increases the likelihood that Moderna’s mRNA flu vaccine will receive final approval from the FDA, potentially transforming seasonal flu prevention. The vaccine’s higher efficacy and adaptable platform could lead to more effective, rapidly developed flu vaccines in the future. If approved, the vaccine could be recommended by the CDC, broadening access and coverage, and offering a new tool in managing seasonal flu outbreaks. This approval also marks a significant milestone in the use of mRNA technology beyond COVID-19, demonstrating its potential for wider vaccine applications.
As an affiliate, we earn on qualifying purchases.
Background on Moderna’s mRNA Flu Vaccine Development and FDA Review Controversy
Moderna’s mRNA-1010, branded as mFlusiva, is based on the same platform used for its COVID-19 vaccines. The development of mRNA flu vaccines aims to provide more effective and adaptable options compared to traditional flu shots. The vaccine’s clinical trials showed promising results, with increased efficacy and immune response.
The review process faced controversy earlier this year when a Trump-appointed FDA official, Vinay Prasad, refused to review Moderna’s application, citing concerns over trial design. This decision was widely criticized and reversed within a week, after which the FDA agreed to evaluate the vaccine. Prasad’s tenure at the FDA ended in April amid other controversial decisions, including the rejection of a gene therapy for Huntington’s disease. Moderna’s current positive review outcome contrasts sharply with this earlier resistance, highlighting ongoing debates over vaccine approval processes.
“The data presented were very well conducted and demonstrate clear, robust efficacy.”
— an anonymous FDA scientist
Remaining Questions About Final FDA Approval and Implementation
It is not yet clear whether the FDA will approve Moderna’s vaccine by the August 5 deadline. Additionally, the status of CDC’s recommendation process is uncertain due to ongoing legal challenges affecting the CDC’s advisory committee, which could influence vaccine adoption and coverage. The impact of these delays on vaccine availability remains to be seen.
Next Steps Toward Widespread Use and Public Access
The FDA is expected to make its final decision by August 5. If approved, Moderna plans to launch the vaccine later this year. The CDC’s Advisory Committee on Immunization Practices (ACIP) will then review the vaccine for recommendation, which is crucial for insurance coverage and federal program inclusion. However, legal challenges to the CDC’s advisory process could delay or complicate this step, making the timeline for widespread public use uncertain.
Key Questions
What is Moderna’s mRNA flu vaccine?
It is a seasonal flu vaccine based on mRNA technology, designed to be more effective and adaptable than traditional flu shots.
Why was there controversy over the FDA’s review process?
A Trump-appointed official initially refused to review Moderna’s application, citing trial design concerns, which was later reversed after widespread criticism.
When will the vaccine be available to the public?
If approved by the FDA by August 5, Moderna plans to release it later this year, pending CDC review and recommendations.
What are the implications of this approval?
This could mark a significant shift in flu vaccination strategies, emphasizing mRNA technology and potentially improving efficacy and response times for seasonal flu.
What hurdles remain before widespread use?
Final FDA approval, CDC recommendation, and legal challenges affecting the CDC’s advisory committee are still unresolved hurdles.
Source: Hacker News
